Marks Group Wealth Management Inc Buys 5,249 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Marks Group Wealth Management Inc increased its stake in IQVIA Holdings Inc by 11.4%, acquiring an additional 5,249 shares during the second quarter, bringing its total holdings to 51,164 shares worth approximately $8.06 million.
• IQVIA reported earnings of $2.81 per share for the last quarter, surpassing estimates, and has set its FY 2025 guidance for earnings per share between $11.750 and $12.050.
• Analysts have a consensus target price of $230.32 for IQVIA, with the stock currently rated as a "Moderate Buy" by 18 investment analysts.

Marks Group Wealth Management Inc grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,164 shares of the medical research company's stock after buying an additional 5,249 shares during the period. Marks Group Wealth Management Inc's holdings in IQVIA were worth $8,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Everpar Advisors LLC raised its position in shares of IQVIA by 4.6% during the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock valued at $221,000 after buying an additional 62 shares during the last quarter. Ballentine Partners LLC raised its position in shares of IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after buying an additional 69 shares during the last quarter. Independent Advisor Alliance raised its position in shares of IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after buying an additional 72 shares during the last quarter. Nemes Rush Group LLC grew its holdings in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after purchasing an additional 81 shares in the last quarter. Finally, Forte Capital LLC ADV grew its holdings in shares of IQVIA by 0.3% in the second quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company's stock valued at $4,225,000 after purchasing an additional 92 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 1.2%

NYSE IQV opened at $206.84 on Monday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34. The firm has a market capitalization of $35.16 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.27 and a beta of 1.32. The company has a fifty day moving average of $187.90 and a two-hundred day moving average of $167.44. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the company earned $2.64 earnings per share. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on IQV. Mizuho raised their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Weiss Ratings reissued a "hold (c)" rating on shares of IQVIA in a report on Saturday, September 27th. Truist Financial raised their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and raised their target price for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, Robert W. Baird raised their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Eighteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $230.32.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.